Cambridge-based Alchemab Therapeutics has added £25m (€29m) to its Series A financing, taking the round to £109m (€128m) and giving the UK biotech fresh capital to advance its AI-enabled antibody pipeline.
AstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona Pharma acquisition.
Boehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines.
Austria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on its AI-enabled platform.
French gene therapy biotech EG 427 has rebranded as Cyllene Therapeutics and raised €33m in a Series C round to push its lead neuro-urology candidate EG110A toward late-stage clinical testing.
Scripta TherapeuticsBiotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and deep disease expertise into drugs more likely to work in patients.
Novartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours.
Roche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast cancer drug Kisqali.
AstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases.
Spanish epigenetics biotech Oryzon Genomics has raised €12m in a capital increase and signed a financing agreement with COFIDES that could add another €25m in future share subscriptions.